Treatment Clinical Trials for Endometrial Cancer

Clinical trials are research studies that involve people. The clinical trials on this list are for endometrial cancer treatment. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 76-81 of 81

  • ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients

    The purpose of this study is to determine how patients with ovarian, fallopian tube, and primary peritoneal cancer will best respond to treatment with rucaparib versus chemotherapy.
    Location: See Clinical Trials.gov

  • Phase 1-2 Study of Onapristone in Patients With Progesterone Receptor Expressing Cancers

    This is a multi-center, open-label, randomized, parallel group two-stage phase 1 study with a phase 2 expansion component in pts with recurrent or metastatic APRpos uterine endometrioid adenocarcinoma. Stage 1: Six dose cohorts, 5 using the extended release tablet (ER) formulation (10 mg BID, 20 mg BID, 30 mg BID, 40 mg BID, 50 mg BID) and 1 using the immediate-release (IR) tablet formulation 100 mg QD will be randomized in parallel. After enrollment of 36 patients in Stage 1, a dose of 50 mg BID was determined to be the RP2D. Stage 2: An additional 10 patients with recurrent or metastatic APRpos uterine endometrioid adenocarcinoma (Stage 2a) will be enrolled at the RP2D. Based on the response in Stage 2a, the cohort will be further expanded by up to 19 more patients to a total of 29 patients to confirm the efficacy and safety profile of onapristone in this selected patient population (Stage 2b).
    Location: See Clinical Trials.gov

  • Chemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer

    Patients with stage 1 & 2 endometrial cancer are treated with surgery. Despite the fact that disease is confound to uterus, unfortunately some of these patients may relapse and die of their disease. Postoperative radiotherapy cannot improve survival. Chemotherapy has shown survival benefit in more advanced stage disease (stage 3 & 4). This study evaluates if one can improve survival in intermediate and high risk early-stage patients by offering them postoperative chemotherapy. This is a randomized phase 3 trial where effect of postoperative chemotherapy is compared with postoperative observation alone (standard strategy). Substudy: Translational research
    Location: See Clinical Trials.gov

  • Talazoparib and Radiation Therapy in Treating Patients with Locally Recurrent Gynecologic Cancers

    This phase I trial studies the side effects and best dose of talazoparib in combination with radiation therapy and to see how well they work in treating patients with gynecologic cancers that have come back after previous treatment. Talazoparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving talazoparib in combination with radiation therapy may work better in treating patients with gynecologic cancers.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Olaparib and Entinostat in Treating Patients with Recurrent, Platinum-Refractory or Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancers

    This phase I / II trial studies the side effects and best dose of olaparib and entinostat and to see how well they work in treating patients with ovarian, primary peritoneal, or fallopian tube cancers that have come back or do not respond to platinum-based chemotherapy. Tumor samples from patients will be tested for a specific change in their genetic materials (DNA) called homologous recombination deficiency (HRD). Patients who lack this genetic change will be eligible to participate in this study. Olaparib and entinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: Vanderbilt University / Ingram Cancer Center, Nashville, Tennessee

  • Rucaparib Camsylate and Nivolumab in Treating Patients with Metastatic Castration-Resistant Prostate Cancer or Advanced or Recurrent Endometrial Cancer

    This phase Ib / IIa trial studies how well rucaparib camsylate and nivolumab work in treating patients with castration-resistant prostate cancer that has spread to other places in the body or endometrial cancer that has come back or has spread to other places in the body. Rucaparib camsylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving rucaparib camsylate and nivolumab may work better in treating patients with castration-resistant prostate or endometrial cancer.
    Location: 2 locations